Jiangxi Dehao New Material Co., Ltd. is located in the ecological industrial park of Tonggu County, Yichun City, Jiangxi Province. The company has created a good situation for its development by leading with innovation, pursuing excellence, deepening reform and constantly generating the endogenous power of development. The company maintains market competitiveness, continuously introduces new products and ensures market share with continuous innovation ability. Dehao New Material ensures the continuous improvement of innovation ability through the continuous introduction of scientific and technological talents, in-depth cooperation with scientific research institutions and high investment in R&D expenses. The primary business of Dehao New Material contains development, production and sales of pharmaceutical intermediates and bulk pharmaceutical chemicals.

With the improvement of people's living standard and lifestyle changes in China, people's demand for medical care has been gradually improved, and the medical security system and community medical environment have been improved. From the perspective of China's population development trend, the population is aging rapidly into the development period, and the incidence of hypertension, work pressure and lifestyle leading to schizophrenia and epidemics is increasing, so these symptomatic treatment Therefore, these allopathic drugs are receiving more and more attention, and the market demand will be increasing, which will further promote the overall development of the drug market.

At present, the company has built a pharmaceutical production base of 50 mu, with an annual output of 500 tons of pharmaceutical intermediates, which have been successfully applied in the synthesis of various drugs such as sartan-based hypertension drugs, epizopapide drugs and aripiprazole drugs. We have also built a pharmaceutical intermediates R&D and testing platform in Tonggu. The R&D team is composed of PhD and master teams from East China University of Science and Technology, Nanchang University and other universities, and the total number of R&D team is above 30, including 5 doctors and 14 masters.